KR20230114698A - 섬유화의 진행 억제제 - Google Patents

섬유화의 진행 억제제 Download PDF

Info

Publication number
KR20230114698A
KR20230114698A KR1020227005324A KR20227005324A KR20230114698A KR 20230114698 A KR20230114698 A KR 20230114698A KR 1020227005324 A KR1020227005324 A KR 1020227005324A KR 20227005324 A KR20227005324 A KR 20227005324A KR 20230114698 A KR20230114698 A KR 20230114698A
Authority
KR
South Korea
Prior art keywords
ser
fibrosis
thr
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227005324A
Other languages
English (en)
Korean (ko)
Inventor
아유미 요시자키
아이 구즈미
신이치 사토
도모유키 후지타
히데키 와타나베
Original Assignee
마루호 코 엘티디
고쿠리츠다이가쿠호우진 도쿄다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마루호 코 엘티디, 고쿠리츠다이가쿠호우진 도쿄다이가쿠 filed Critical 마루호 코 엘티디
Publication of KR20230114698A publication Critical patent/KR20230114698A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227005324A 2020-11-30 2021-11-29 섬유화의 진행 억제제 Pending KR20230114698A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPPCT/JP2020/044406 2020-11-30
PCT/JP2020/044406 WO2022113316A1 (ja) 2020-11-30 2020-11-30 線維化の進行抑制剤
PCT/JP2021/043543 WO2022114165A1 (ja) 2020-11-30 2021-11-29 線維化の進行抑制剤

Publications (1)

Publication Number Publication Date
KR20230114698A true KR20230114698A (ko) 2023-08-01

Family

ID=81754505

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227005324A Pending KR20230114698A (ko) 2020-11-30 2021-11-29 섬유화의 진행 억제제

Country Status (12)

Country Link
US (1) US20240084020A1 (https=)
EP (1) EP4252771A4 (https=)
JP (3) JPWO2022113316A1 (https=)
KR (1) KR20230114698A (https=)
CN (1) CN116829187A (https=)
AU (1) AU2021385871A1 (https=)
CA (1) CA3199351A1 (https=)
CL (1) CL2023001460A1 (https=)
IL (1) IL303159A (https=)
MX (1) MX2023006164A (https=)
TW (1) TW202237182A (https=)
WO (2) WO2022113316A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) * 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Gastrointest Liver Physiol 2011;300:G723-8.
Fiocco U, Rosada M, Cozzi L, et al. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis 1993;52:272-7.
Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
Hasegawa M, Fujimoto M, Kikuchi K, et al. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328-32.
Kalogerou A, Gelou E, Mountantonakis S, et al. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005;64:1233-5.
Koch AE, Kronfeld-Harrington LB, Szekanecz Z, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Pathobiology 1993;61:239-46.
Kopf M, Le GG, Bachmann M, et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245-8.
Lai T, Wu D, Li W, et al. Interleukin-31 expression and relation to disease severity in human asthma. Sci Rep 2016;6:22835.
Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med 2001;194:809-21.
Lei Z, Liu G, Huang Q, et al. SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. Allergy 2008;63:327-32.
Nattkemper LA, Martinez-Escala ME, Gelman AB, et al. Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin. Acta Derm Venereol 2016;96:894-8.
Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006;118:930-7.
Ohmatsu H, Sugaya M, Suga H, et al. Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. Acta Derm Venereol 2012;92:282-3.
O'Reilly S, Ciechomska M, Cant R, et al. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem 2014;289:9952-60.
O'Reilly S, Hugle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 2012;51:1540-9.
Postlethwaite AE, Holness MA, Katai H, et al. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479-85.
Raap U, Wichmann K, Bruder M, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 2008;122:421-3.
Rincon M, Anguita J, Nakamura T, et al. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997;185:461-9.
Roumm AD, Whiteside TL, Medsger TA, et al. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53.
Salmon-Ehr V, Serpier H, Nawrocki B, et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 1996;132:802-6.
Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
Shi K, Jiang J, Ma T, et al. Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice. Respir Physiol Neurobiol 2014;190:113-7.
Taki Z, Gostjeva E, Thilly W, et al. Pathogenic Activation of Mesenchymal Stem Cells is induced by the Disease Microenvironment in Systemic Sclerosis. Arthritis Rheum [Epub ahead of print: 31 Mar 2020].
Yamamoto T, Takagawa S, Katayama I, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456-62.
Yaseen B, Lopez H, Taki Z, et al. Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology (Oxford). [Epub ahead of print: 4 May 2020].
Yoshizaki A, Yanaba K, Iwata Y, et al. Cell Adhesion Molecules Regulate Fibrotic Process via Th1/Th2/Th17 Cell Balance in a Bleomycin-Induced Scleroderma Model. J Immunol 2010;185:2502-15.
Yoshizaki A, Yanaba K, Ogawa A, et al. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum 2011;63:3086-97.
Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett 2018;195:76-82.

Also Published As

Publication number Publication date
EP4252771A4 (en) 2024-10-23
JP2022095913A (ja) 2022-06-28
CA3199351A1 (en) 2022-06-02
TW202237182A (zh) 2022-10-01
MX2023006164A (es) 2023-07-28
WO2022114165A1 (ja) 2022-06-02
CN116829187A (zh) 2023-09-29
IL303159A (en) 2023-07-01
JPWO2022114165A1 (https=) 2022-06-02
WO2022113316A1 (ja) 2022-06-02
US20240084020A1 (en) 2024-03-14
AU2021385871A9 (en) 2024-05-02
JP7802601B2 (ja) 2026-01-20
AU2021385871A1 (en) 2023-06-22
CL2023001460A1 (es) 2023-12-01
JPWO2022113316A1 (https=) 2022-06-02
EP4252771A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
KR101345586B1 (ko) Ｉｌ-31 길항제를 사용한 신경세포 조직의 통증 및 염증 치료 방법
US20060039910A1 (en) Methods and compositions for treating allergic inflammation
JP2011514881A (ja) 免疫増強剤としてのｔａｍ受容体阻害剤の使用および免疫抑制剤としてのｔａｍ活性化剤の使用
US20110142833A1 (en) Methods for treating and preventing fibrosis
KR20190138806A (ko) C5a 활성 억제제에 의한 염증 질병의 치료
JP2016153426A (ja) アネキシン−１（リポコルチン１）をモジュレートすることによる自己免疫疾患の処置方法
JP7802601B2 (ja) 線維化の進行抑制剤
US11406686B2 (en) Methods for the treatment of tissue lesions with CCR2 agonists
CN101730545A (zh) 用于治疗肾病的化合物和方法
HK40092050A (zh) 纤维化进展的抑制剂
KR20210060359A (ko) 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물
EA050619B1 (ru) Ингибитор прогрессирования фиброза
KR20250044344A (ko) 아토피 피부염의 치료에 유용한 il-15 저해제
CN113975372A (zh) 一种采用激动剂抑制银屑病的方法
JP7576847B2 (ja) 免疫応答抑制剤
WO2024011946A1 (en) Polypeptide dimers for the treatment of systemic sclerosis
EP2913060A1 (en) Inhibition of the fractalkine-receptor interaction for the treatment of atopic dermatitis
WO2012002775A2 (ko) 뉴로필린１ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법
Potomkina et al. Lishchuk-Yakymovych K., Chopyak V.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241127

Comment text: Request for Examination of Application